Obesity and Semaglutide: Benefits and Risks

Obesity is a widespread health issue that places a significant burden on healthcare systems around the world. It is also associated with an increased risk of developing chronic conditions such as type 2 diabetes, cardiovascular disease, hypertension, and certain types of cancer. This condition, defined by the WHO as an excessive accumulation of body fat that impairs health, results from a combination of genetic, environmental, behavioral, and metabolic factors. The growing prevalence of obesity, along with the aging global population, has driven the medical and scientific communities to develop treatments that not only support weight loss but also address the underlying metabolic mechanisms. In this context, semaglutide has emerged as a promising medication for managing obesity. It is seen as a tool to enhance the effectiveness of non-pharmacological strategies, such as lifestyle changes, balanced nutrition, and physical activity. However, its popularity on social media—often driven by celebrity endorsements for cosmetic purposes—has raised concerns among health authorities about the potential misuse of the drug. It is therefore important to review what semaglutide is, along with its benefits and risks. The following is a summary of this information.

Institutions

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2025-05-05
DOI
https://doi.org/10.5281/zenodo.15346190
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Obesity and Semaglutide: Benefits and Risks

Zenodo (CERN European Organization for Nuclear Research)
Diabetes Treatment and Management
article

Obesity and Semaglutide: Benefits and Risks

article en

Abstract

Obesity is a widespread health issue that places a significant burden on healthcare systems around the world. It is also associated with an increased risk of developing chronic conditions such as type 2 diabetes, cardiovascular disease, hypertension, and certain types of cancer. This condition, defined by the WHO as an excessive accumulation of body fat that impairs health, results from a combination of genetic, environmental, behavioral, and metabolic factors. The growing prevalence of obesity, along with the aging global population, has driven the medical and scientific communities to develop treatments that not only support weight loss but also address the underlying metabolic mechanisms. In this context, semaglutide has emerged as a promising medication for managing obesity. It is seen as a tool to enhance the effectiveness of non-pharmacological strategies, such as lifestyle changes, balanced nutrition, and physical activity. However, its popularity on social media—often driven by celebrity endorsements for cosmetic purposes—has raised concerns among health authorities about the potential misuse of the drug. It is therefore important to review what semaglutide is, along with its benefits and risks. The following is a summary of this information.

Zenodo (CERN European Organization for Nuclear Research)
Accident Compensation Corporation (NZ), Universidad Nacional de Colombia (CO)
Openalex Percentile: Top 42%
Diabetes Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Obesity and Semaglutide: Benefits and Risks · Zenodo (CERN European Organization for Nuclear Research) (2025) | TGRS Research Map | TGRS